Article
Molecular Alterations of <i>KIT</i> Oncogene in Gliomas
1 Jan 2007
Abstract excerpt
Gliomas are the most common and devastating primary brain tumours. Despite therapeutic advances, the majority of gliomas do not respond either to chemo or radiotherapy. KIT, a class III receptor tyrosine kinase (RTK), is frequently involved in tumourigenic processes. Currently, KIT constitutes an attractive therapeutic target. In the present study we assessed the frequency of KIT overexpression in gliomas and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
